
What happened
The Nikkei average continued its sharp decline, ending the morning session down 1,082.58 yen at 61,825.26 on volume of about 1.36 billion shares, with selling concentrated in semiconductor-related stocks.
Why it matters
The drop reflects worsening investor sentiment, with the index briefly widening its loss to the 1,400 yen level and falling below the 62,000 mark, signaling a continued adjustment phase.
Summaries like this, every morning.
The morning session on the Tokyo Stock Exchange saw the Nikkei average extend its losses, following a mixed U.S. market where the Dow edged up while the Nasdaq dropped sharply. The divergence stemmed from earnings reports by Meta Platforms and Tesla, which rekindled worries about overinvestment in artificial intelligence. That sentiment spilled over into Japan, where high-priced semiconductor-related stocks led the decline, and selling spread to electronic components and machinery.
At the same time, falling U.S. long-term interest rates, driven by fading expectations for additional rate hikes within the year, weighed on bank stocks. Conversely, defensive and domestic-demand shares such as real estate and retail attracted safe-haven buying. The Nikkei briefly widened its loss to the 1,400 yen level before stabilizing in the 61,800 range. Market participants are now watching whether the rotation into defensive stocks will persist in the afternoon.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Anthropic released Claude Haiku 4.5, which it says matches Claude Sonnet 4's coding performance at one-third t…

Intel published a narrated demo walking viewers through how CrowdStrike Falcon Data Security and Intel Core Ul…

Salesforce announced Oct

Pfizer says rolling out AI and advanced analytics across R&D, manufacturing and commercial operations has alre…

Honeywell Technologies announced commercial availability of TrackWise Digital's AI Processing Agent, which aut…

Bristol Myers Squibb entered multi-year AI drug development partnerships with Pathos AI and Tempus AI
